TEVA PHARMACEUTICALS
By: Kaity Brown
About Teva




Established in 1901. Became TEVA
pharmaceuticals in the 1930s
Currently their headquarters is in Israel and
are active in 60 countries.
Aim is to produce drugs in specialty areas
such as CNS, Respiratory, Women’s Health,
Oncology, and Biologicals as well as be a
major generic manufacturer.
Income is 1.96 billion. Have 20.32 billion in
sales, and a debt/Equity ratio of 0.65
Products

CNS and Pain Products:
 AZILECT [Parkinson’s]
 NUVIGIL


[Sleep Disorders]
Respiratory Products
 PROAIR HFA
Estimated 1.5 million prescriptions are filled
daily in US with their generic products
January 24, 2013


January 23: Releases reports from the
second Phase III Trial for Nuvigil to be
used with major depression associated
with bipolar disorder came back negative.
Stock Range: $37.24-$38.22
January 31, 2013


January 31: Announced termination of
their collaboration with CureTech which
is a company that worked with a
monoclonal antibody for treating tumors
and malignancies.
Stock Range: $37.35-$38.15
February 7, 2013
•
February 2: enrolled 1st patient into a phase 4 trial
for Azilect for the treatment of mild cognitive
impairment in Parkinson’s disease with plans for
it to be the largest ever.


Currently used as an initial treatment for Parkinson’s.
February 7: Released 2012 financial report
4th Quarter net revenue: $5.2 billion, $2.6 billion from
US which was a 14% decrease from 2011.
 Full Year net revenue: $20.3 billion.
 15% increase in quarterly dividend.
 Found that specialty drugs are higher than generic
sales in US and both have declined since 2011.
 Shares have decreased 15% over past year.

Stock Range: $37-$38.16
February 21, 2013
February 19: Seeking Alpha wrote an
article mentioning Teva as stocks that will
be promising for improvement and a
company to watch for for 2013.
 February 14: FDA approves the ANDA
for Teva’s new generic Adderall XR.


Stock Range: $37.96-$38.96
February 28, 2013
February 22: Announced they will present
data for the improvement of sleep quality
and relief with QNASL at Annual Allergy
Meeting
 February 25: Featured Healthcare Laggard
because stocks fell .50, or 1.9% over the
day
 Stock Range: $37.23-$38.45

March 7, 2013



March 6: Enrolled 1st patient in phase III trials
for Concerto for RRMS. Goal is to improve
disability progression.
March 1: Called for redemption on
approximately $500 million in outstanding
principal amount of 5.55% Senior Notes.
Stock Range: $37.11-$39.63
 Lowest
point fell on March 1st.
March 21, 2013




March 13: Announced that they and Band Against
MS, a foundation formed by country music singer
Clay Walker, have joined together for the “Stick
With It!” campaign. Purpose is to educate patients
with RRMS about the importance of adherence for
long term management
March 14: Will pay $2.25 million for
environmental penalties including leaking a
fluorescent green discharge into a Missouri River.
March 14: Released information of studies on
AZILECT, COPAXONE, and ALLEGRO and
announced to present it at the American Academy
of Neurology annual meeting
Stock Range: $40-$41.50
March 28, 2013


March 27: Considered to be one of 4 that is
dragging the drug industry down
March 28: Released 14 to 10 experts say hold
instead of buy. Given a ratings score of C+
 Positives:
good cash flow and solid financial
position
 Negatives: deteriorating net income, disspointing
equity return, and bad stock performance

Stock Range: $39.32-$40.29
April 4, 2013



March 29: FDA approves NDA for Quartette
birth control.
April 1: The Motley Fool posted a video about
if Teva stock is still worth owning? Reported
yes because of dividend increases, small
amount of debt, and the promising sale
increase with ObamaCare
Stock Range: $39.25-$39.86
Buy, Sell, or Hold?




As of now, stocks are at about $39.45/share
Rating 5 out of 10
Current recommendation is to Hold any stocks
owned or sell.
No significant growth in stock value despite a
sales growth of 10.9%

Income growth = -28.9%

No new exciting drugs seem to be in the pipeline.

Sources: MSN Money and TevaPharm.com